Revvity (RVTY) Asset Writedowns and Impairment (2013 - 2023)
Revvity's (RVTY) quarterly Asset Writedowns and Impairment came in at -$3.9 million in Q1 2023, down 148.73% quarter-over-quarter from $7.9 million in Q1 2021.
Powered by 
Analysis
Revvity (RVTY) Asset Writedowns and Impairment (2013 - 2023) Analysis & Trends
Revvity (RVTY) has reported Asset Writedowns and Impairment for 3 consecutive years, with -$3.9 million the latest figure, recorded in Q1 2023.
- For the quarter ending Q1 2023, Asset Writedowns and Impairment changed N/A year-over-year to -$3.9 million; the trailing twelve-month figure through Dec 2023 stood at $4.3 million (changed N/A YoY), and the FY2025 full-year result was $4.8 million, down 79.03% from the prior year.
- Asset Writedowns and Impairment fell to -$3.9 million in Q1 2023 per RVTY's latest filing, from $7.9 million in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $7.9 million in Q1 2021 and bottomed at -$3.9 million in Q1 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jan 1, 2023 | -3.87 Mn |
| Jan 3, 2021 | 7.94 Mn |
| Dec 29, 2013 | 200,000.00 |